Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid phosphate versus active comparator for pediatric acute bacterial skin and skin structure infections
2016-003884-20Phase 3
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tedizolid in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall safety assessment of tedizolid phosphate.
02
Drugs
tedizolid
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on 2016-003884-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003884-20.